Olmesartan and intestinal adverse effects in the ROADMAP study

Mayo Clinic Proceedings

Volumn 87, Issue 12, 2012, Pages 1230-1231

  Menne, Jan ^a   Haller, Hermann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OLMESARTAN; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; EPIGASTRIC DISCOMFORT; FATIGUE; FLATULENCE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL PAIN; HUMAN; IRRITABLE COLON; LETTER; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; VOMITING; WEIGHT REDUCTION;

EID: 84872965041     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.10.005     Document Type: Letter

References (3)

1. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732-738.
2. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907-917.
3. Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens. 2006;24(2):403-408.